Lusvertikimab

芦维奇单抗

Report date: 2025/02/26 16:24:20
First In Class

Base Information

Drug NameLusvertikimab
Drug Alias NameOSE-127S-95011Effi-7OSE-217
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-7 receptor subunit alpha antagonists
TargetsInterleukin-7 receptor subunit alpha
Therapy Area/IndicationsColitis, UlcerativeSjogren's Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaUnited States +[17] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEffimune
China Registration ClassN/A

Develop Information

Active CompaniesInstitut De Recherches Internationales ServierOse Immunotherapeutics
Inactive CompaniesN/A
Active IndicationsColitis, UlcerativeSjogren's Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A